Astragaloside IV for Experimental Focal Cerebral Ischemia: Preclinical Evidence and Possible Mechanisms

Table 3

Risk of bias of the included studies.

Study	A	B	C	D	E	F	G	H	I	J	Total
Sun et al. 2014 [8]	√		√			√					3
Huang et al. 2013 [9]	√	√	√								3
Xu and Chen 2011 [10]	√	√	√								3
Li et al. 2012 [11]	√	√	√	√	√	√			√	√	8
Luo et al. 2004 [12]	√	√	√			√			√		5
Li et al. 2013 [13]	√	√	√	√	√	√			√	√	8
Zhang et al. 2013 [14]	√		√							√	3
Zhou and Liu 2008 [15]	√	√	√		√	√					5
Cao et al. 2015 [16]	√		√		√	√			√	√	6
Yang et al. 2012 [17]	√		√			√			√	√	5
Cao et al. 2014 [18]	√	√	√		√	√			√		6
Yin et al. 2010 [19]	√	√	√			√			√		5
Luo and Qin 2000 [20]	√		√			√					3

Note. Studies fulfilling the criteria of A: peer reviewed publication; B: control of temperature; C: random allocation to treatment or control; D: blinded induction of model; E: blinded assessment of outcome; F: use of anesthetic without significant intrinsic neuroprotective activity; G: animal model (aged, diabetic, or hypertensive); H: sample size calculation; I: compliance with animal welfare regulations; J: statement of potential conflict of interests.